NCIC CLINICAL TRIALS GROUP
LOCALIZED PROSTATE

GU DISEASE ORIENTED GROUP MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

ROOM: WHISTLER

APRIL 30TH, 2011 – 7:30 AM – 9:00 AM

CO-CHAIRS: A. LOBLAW & N. FLESHNER

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
- To understand and address, through clinical and translational research, the disease burden associated with localized prostate cancer in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to localized prostate cancer.
- To update, review, and discuss recent results of clinical studies conducted by the NCIC Clinical Trials Group and/or by national/ international collaborators.
- To provide a learning environment supportive to new investigators.
- To understand and apply new clinical trial methodologies in the field of clinical research related to localized prostate cancer.

7:30 am  Welcome  
A. Loblaw & N. Fleshner

Ongoing study proposals:
7:35 am  Phase III Study of HDR Brachytherapy in Intermediate Risk CaP  
E. Vigneault/ A. Loblaw

New study proposals:
8:00 am  Low risk prostate cancer:  
AS trial dutasteride +- MDV3100  
N. Fleshner

8:15 am  High risk prostate cancer:  
Conventional vs Hypofractionation for high risk localized prostate cancer: A Phase 3 Randomized Study  
P. Cheung

8:30 am  Randomized Phase II Trial of Degarelix vs LHRH Agonist therapy in High Risk Prostate Cancer  
S. Malone

8:45 am  Prostatectomy vs Radiation for High Risk Prostate Cancer  
R. Nam

9:00 am  Meeting Adjourned